LONZA GROUP ADR
LZAGY
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
123.1% downsideOvervalued by 123.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.57 (0.94%) |
| Earnings per Share | $1.36 |
| Beta | 0.83 |
| Outstanding Shares | 701,090,600 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -136.38 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▼ 0.01% |
|---|---|
| Total Invested | $14.63M▼ 28.06% |
| Investors Holding | 14▼ 2.00% |
ESG Score
No data
About
No data
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending (like Medicare pricing), all of which directly affect Lonza's corporate profitability as a multinational manufacturer and the revenue streams of its pharmaceutical clients.
This committee directly allocates federal spending, including for scientific research (e.g., NIH, BARDA) and healthcare procurement, directly influencing the funding available for projects that Lonza's clients undertake and potentially direct contracts.
This committee directly regulates the FDA and NIH, which are critical for drug approval, research funding, and the overall operational environment for Lonza's clients in the pharmaceutical and biotech sectors.
Members receive classified briefings on global threats, including potential biothreats or pandemics, which could directly influence the demand for drug development and manufacturing services, creating high informational asymmetry for biotech CDMOs like Lonza.